In conclusion, we have demonstrated that PPARGC1A-mediated mitochondrial respiration can be considered a potential therapeutic target in tRCC. This evidence concerns the gene PPARGC1A and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.